checkAd
    Appili Therapeutics Registered (A) Aktie
    0,0295
     
    USD
    +7,66 %
    +0,0021 USD
    Letzter Kurs 27.04.24 Nasdaq OTC
    ISIN: CA03783R1073 · WKN: A2PVQK · SYM: APLIF · Kanada

    Neueste Nachrichten

    Appili Therapeutics Announces Additional Bridge Loan from Bloom Burton & Co.
    27.04.24 · globenewswire · Appili Therapeutics Registered (A)
    Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD)
    02.04.24 · Business Wire (engl.) · Appili Therapeutics Registered (A)
    Appili Therapeutics Signs Definitive Agreement to be Acquired by Aditxt, Inc.
    02.04.24 · globenewswire · Appili Therapeutics Registered (A)
    Researchers Publish Manuscript on the Prevention and Emergency Response to Tularemia Outbreaks
    12.03.24 · globenewswire · Appili Therapeutics Registered (A)
    Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2024
    13.02.24 · globenewswire · Appili Therapeutics Registered (A)
    Appili Therapeutics Announces Issuance of Patent for ATI-1701 Biodefense Vaccine Candidate to Protect Against Tularemia and Provides Update on Bridge Loan
    15.12.23 · Business Wire (engl.) · Appili Therapeutics Registered (A)
    Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2024
    13.11.23 · Business Wire (engl.) · Appili Therapeutics Registered (A)
    Appili Therapeutics’ Biodefense Vaccine Candidate ATI-1701 is Awarded Additional Funding from the U.S. Air Force Academy
    25.10.23 · Business Wire (engl.) · Appili Therapeutics Registered (A)
    Appili Therapeutics Announces Results of Annual Meeting of Shareholders and Provides Corporate Update
    28.09.23 · Business Wire (engl.) · Appili Therapeutics Registered (A)
    Appili Therapeutics Presents at the 10th International Tularemia Conference
    27.09.23 · Business Wire (engl.) · Appili Therapeutics Registered (A)
    Appili Therapeutics Announces U.S. FDA Approval of LIKMEZ (ATI-1501) Metronidazole Oral Suspension
    25.09.23 · Business Wire (engl.) · Appili Therapeutics Registered (A)
    Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2024
    11.08.23 · Business Wire (engl.) · Appili Therapeutics Registered (A)